Morpheus8V

Morpheus8V is a radiofrequency microneedling device applied to vulvar and vaginal tissue. We offer it, and we describe it here with more caution than most practices do, because the marketing around energy-based vaginal treatments has run well ahead of the evidence. It is an elective cosmetic procedure for specific concerns about laxity and vulvar appearance. It is not a treatment for genitourinary syndrome of menopause, and we will not present it as one.

What the device actually is

Morpheus8V is a handpiece on a radiofrequency microneedling platform, adapted with internal and external applicators for vaginal and vulvar use. Fine insulated needles penetrate the tissue to a set depth and deliver radiofrequency energy at the tip, producing controlled thermal injury in the dermis or submucosa while sparing the surface. The intended biological effect is the same as it is elsewhere on the body: a wound healing response with collagen and elastin remodeling over the following weeks to months. The external applicator is used on the labia and surrounding skin, the internal one within the vaginal canal.

That is a real mechanism, and it is not in dispute that radiofrequency microneedling remodels dermal collagen; the technology is well established in facial and body treatment. The open question is whether producing that remodeling in vaginal and vulvar tissue leads to the clinical outcomes it is marketed for. Demonstrating a change in tissue is not the same as demonstrating that a symptom improves, and that second claim requires a different kind of evidence than the first.

What the evidence does and does not show

In 2018 the FDA issued a safety communication warning against the use of energy-based devices for procedures marketed as vaginal rejuvenation, stating that the agency had not cleared or approved any such device for the treatment of menopausal vaginal symptoms, sexual function, or urinary incontinence, and that it had received reports of adverse events including burns, scarring, and chronic pain. No energy-based device has since been cleared for those indications. Morpheus8V is not FDA-cleared to treat vaginal atrophy, sexual dysfunction, or incontinence, and any practice implying otherwise is describing an off-label use as though it were an approved one.

The published research on energy-based vaginal treatment consists largely of small, uncontrolled studies reporting symptom scores that improved after treatment. Studies of that design reliably produce positive results in conditions with a substantial placebo component, and sexual comfort is exactly such a condition. Where sham-controlled trials have been conducted, most notably with fractional CO2 laser for genitourinary syndrome of menopause, the treated groups have generally not outperformed sham. The radiofrequency literature is thinner still and adequately controlled trials are largely absent. That does not prove the treatment is inert; it means the evidence to support it has not yet been produced.

Set against that, low-dose vaginal estrogen for genitourinary syndrome of menopause has randomized evidence, decades of clinical experience, a well-characterized safety profile, and a cost of a few dollars a week. If dryness, burning, painful sex, or recurrent urinary infection is what brought you here, that is the treatment we will recommend first. We will want it properly tried and given enough time to work before an elective procedure is discussed at all.

Where it may reasonably fit

There is a category of concern that hormonal treatment does not address: the appearance and texture of the vulvar skin, laxity of the external tissues after childbirth or weight change, crepiness of the labia majora, and a subjective sense of looseness that persists after the tissue itself has been treated. These are cosmetic and functional-cosmetic concerns, and they are legitimate ones to want addressed. Morpheus8V is offered for those, as an elective procedure, with the limits of the evidence stated in advance.

What we will not do is offer it as a substitute for treating genitourinary syndrome of menopause, or as a way to avoid vaginal estrogen in a woman who could safely use it, or as a treatment for stress incontinence or prolapse, both of which have effective evidence-based management including pelvic floor physical therapy, pessaries, and surgery. If incontinence is your main concern, urology is in-house and that is the right conversation to have first. Where a patient has already been through the evidence-based options, understands what is known and unknown, and still wants to proceed for cosmetic reasons, that is an informed choice and we will support it.

A device can be safe, plausible, and still unproven. You are entitled to know which of those three we are standing on when we recommend something.

What a session involves

You are examined first, and we confirm that cervical screening is current and that there is no active infection, unexplained bleeding, or untreated skin condition. Topical anesthetic is applied roughly thirty to forty-five minutes before treatment, and local anesthetic is sometimes added for external work. Most patients describe the external treatment as a hot prickling sensation with pressure, and the internal treatment as more pressure than pain, since the vaginal canal has relatively few somatic pain fibers. Treatment time is typically twenty to forty minutes depending on the areas covered.

Afterward the treated skin is usually pink and swollen, sometimes with a grid pattern of tiny marks that fades within a few days, and there may be light spotting or discharge. Most people return to normal activity the same or the next day. We advise avoiding intercourse, tampons, swimming, and hot tubs for about a week, and avoiding heavy exercise for the first couple of days. Serious complications are uncommon but they exist, and the FDA communication listed burns, scarring, and persistent pain among the reports it received; those risks are part of the consent conversation rather than a footnote to it.

Sessions, cost, and candidacy

A typical course is three sessions spaced four to six weeks apart, with collagen remodeling continuing for some months after the last one, and some patients choose an annual maintenance session. Results vary considerably between individuals and we will not quote you a figure for expected improvement, because the data to support such a figure do not exist. Because the procedure is cosmetic and elective, it is not covered by insurance; we quote the full cost in writing before you book, and there are no package obligations.

It is not appropriate during pregnancy, with an active genital infection, with undiagnosed vaginal bleeding, with an implanted electronic device such as a pacemaker, or where there is a history of keloid scarring. If you are perimenopausal or postmenopausal, we will usually want tissue health optimized with vaginal estrogen first, both because it may be all you need and because treating healthier tissue is preferable. Anyone who comes in asking about vaginal rejuvenation gets a full assessment before a device is discussed, because in a meaningful proportion of cases the underlying problem turns out to be one with a better and cheaper answer.